News and Updates

• 04/09/2012 -
• Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound

• 03/26/2012 -
• Sunshine Biopharma and Binghamton University to Present New Data at the Upcoming American Association for Cancer Research Meeting in Chicago

• 11/28/2011 -
• Avastin Ousted by FDA for Breast Cancer, Sunshine Biopharma Gears-Up for Clinicals

• 11/15/2011 -
• Sunshine Biopharma's Announces Successful Completion of Preclinical Studies for Adva-27a, The Company's Lead Anti-Cancer Compound

• 10/05/2011 -
• Sunshine Biopharma's Anti-Cancer Compound, Adva-27a, found to be a Topoisomerase II Inhibitor

• 08/30/2011 -
• Clearance of Sunshine Biopharma's Anti-Cancer Compound, Adva-27a, Does Not Involve a Toxic Intermediate

• 07/27/2011 -
• Sunshine Biopharma Looking to Mimic Roche's Billion Dollar Cancer Drug Success

• 07/25/2011 -
• Sunshine Biopharma's Lead Anti-tumor Compound, Adva-27a, is cleared via a cytochrome P450-Independent Mechanism

• 07/11/2011 -
• Sunshine Biopharma’s Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells

• 06/27/2011 -
• Sunshine Biopharma's Lead Anti-Cancer Compound, Adva-27a, performs exceptionally well in human microsome stability assays

• 06/17/2011 -
• Sunshine Biopharma enters into clinical trials agreement with the Jewish General Hospital in Montreal, Canada

• 04/26/2011 -
• Sunshine Biopharma’s CEO Does Live Interview on ChartPoppers.com

• 04/01/2011 -
• Sunshine Biopharma to appear at American Association for Cancer Research Meeting

• 03/04/2011 -
• CEO CFO Interviews Dr. Steve N. Slilaty

• 02/25/2011 -
• Interview with Central NY Business Journal